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Abstract
Background: The identification of smoking-related lung disease in current and former smokers with normal FEV1 is
complex, leading to debate regarding using a ratio of forced expiratory volume in 1 s to forced vital capacity (FEV1/FVC)
of less than 0.70 versus the predicted lower limit of normal (LLN) for diagnosis of airflow obstruction. We hypothesized
that the discordant group of ever-smokers with FEV1/FVC between the LLN and 0.70 is heterogeneous, and aimed to
characterize the burden of smoking-related lung disease in this group.
Methods: We compared spirometry, chest CT characteristics, and symptoms between 161 ever-smokers in the discordant
group and 940 ever-smokers and 190 never-smokers with normal FEV1 and FEV1/FVC > 0.70 in the SPIROMICS cohort. We
also estimated sensitivity and specificity for diagnosing objective radiographic evidence of chronic obstructive pulmonary
disease (COPD) using different FEV1/FVC criteria thresholds.
Results: The discordant group had more CT defined emphysema and non-emphysematous gas trapping, lower post-
bronchodilator FEV1 and FEF25–75, and higher respiratory medication use compared with the other two groups. Within the
discordant group, 44% had radiographic CT evidence of either emphysema or non-emphysematous gas trapping; an
FEV1/FVC threshold of 0.70 has greater sensitivity but lower specificity compared with LLN for identifying individuals with
CT abnormality.
Conclusions: Ever-smokers with normal FEV1 and FEV1/FVC < 0.70 but > LLN are a heterogeneous group that includes
significant numbers of individuals with and without radiographic evidence of smoking-related lung disease. These
findings emphasize the limitations of diagnosing COPD based on spirometric criteria alone.
Keywords: Chronic obstructive pulmonary disease, Pulmonary function tests, Spirometry, Airway obstruction,
Emphysema, Forced expiratory volume, Maximal Midexpiratory flow rate
Background
Airflow obstruction is a hallmark of chronic obstructive
pulmonary disease (COPD), and by current recommen-
dations [1] is confirmed by a reduced ratio of forced ex-
piratory volume in 1 s (FEV1) to forced vital capacity
(FVC). To simplify the diagnosis of airflow obstruction,
a fixed cut-off ratio of FEV1/FVC (FEV1/FVC < 0.70) is
often used instead of predicted lower limit of normal
(LLN) (FEV1/FVC < LLN), defined as the lower fifth per-
centile of a reference population. [2, 3]
Because the predicted normal FEV1/FVC declines with
age, a fixed cut-off ratio of FEV1/FVC < 0.70 has the poten-
tial for misclassification and over diagnosis in the elderly,
[4–10] while using predicted LLN may better predict ad-
verse clinical outcomes [11] and more accurately predict
all-cause mortality. [4] Although there is a group of youn-
ger individuals for whom LLN is > 0.7, a particular chal-
lenge is presented by subjects who fall in a “discordant”
group with FEV1/FVC ratio > LLN but < 0.7. Compared to
subjects with FEV1/FVC > 0.70, the individuals in this
* Correspondence: Cheryl.pirozzi@hsc.utah.edu
1Division of Pulmonary and Critical Care Medicine, Department of Internal
Medicine, University of Utah, 26 N 1900 E, Salt Lake City, UT 84132, USA
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pirozzi et al. Respiratory Research          (2018) 19:223 
https://doi.org/10.1186/s12931-018-0911-z
discordant group have been found to have greater emphy-
sema, airway wall thickening, and gas trapping, as well as
greater risk for chronic obstructive pulmonary disease
(COPD)-related hospitalization, emergency department
visits, and mortality [12–16]. There has been recent interest
in characterizing patients with mild smoking-related lung
disease as evidenced by symptoms and radiographic abnor-
malities despite normal spirometry, [17, 18] highlighting
the limitations of using spirometric criteria alone for diag-
nosis of COPD. We hypothesized that the discordant
group of ever-smokers with FEV1/FVC between the LLN
and 0.70 is heterogeneous, containing some individuals
with smoking-related lung disease and some with changes
in lung function related to aging. We address this hypoth-
esis by characterizing clinical, radiographic and physio-
logic features of ever-smokers in this discordant group
and comparing them with the group of individuals with
FEV1/FVC > 0.70.
1
Methods
SPIROMICS study methods
SPIROMICS is a multicenter prospective cohort study that
has enrolled 2981 participants including never-smokers,
smokers without airway obstruction and smokers with
mild, moderate and severe COPD, with the goals of identi-
fying new COPD subgroups and intermediate markers of
disease progression [19]. Participants were 40–80 years old
at baseline. “Smokers” were defined as current or former
smokers with lifetime smoking history of greater than 20
pack-years. The study design and exclusion criteria have
previously been described [19]. The research protocol was
approved by the institutional review boards of all participat-
ing institutions and all participants gave written informed
consent.
Subjects and measure of exposure
We analyzed data for three groups of subjects included
in SPIROMICS: Group 1) current or former smokers
(ever-smokers) with normal post-bronchodilator FEV1
and FEV1/FVC > LLN but < 0.70 (discordant group, n =
161); Group 2) ever-smokers with normal FEV1 and
FEV1/FVC > 0.70 (n = 940); and Group 3) never-smokers
with normal FEV1 and FEV1/FVC > 0.70 (n = 190). In a
supplementary analysis we also compared outcomes with
a Group 4) patients with FEV1/FVC in the 75% quartile
of those less than LLN (n = 379).
Pulmonary function methods
Pulmonary function testing was performed and inter-
preted according to the 2005 ATS/ERS guidelines;
post-bronchodilator spirometric measurements were used
for analysis [20, 21]. NHANES III spirometric references
values were used to calculate percent predicted values and
LLN [22].
Outcomes
We compared respiratory symptoms, quality of life,
medication use, CT metrics, FEV1% predicted, forced ex-
piratory flow rate between 25 and 75% of FVC or max-
imum mid-expiratory flow (FEF25–75), 6 min walk
distance (6MWD), and two prospective variables: annual
FEV1 change and exacerbation rate, between the three
groups. Chronic bronchitis was defined as patient re-
ported cough with sputum for at least 3 months for
≥2 years. Dyspnea was defined by the modified Medical
Research Council (mMRC) dyspnea score, [23] stratified
into two groups as mMRC ≥2 (moderate or severe dys-
pnea) vs mMRC 0–1 (mild or no dyspnea). Respiratory
symptoms were also measured by the COPD Assessment
Test (CAT) [24]. Quality of life was measured by the St.
George’s Respiratory Questionnaire (SGRQ) [25]. Medi-
cation use was defined as patient-reported regular use of
inhaled bronchodilators and/or inhaled steroid. Annual
FEV1 change was defined using a regression model that
incorporated the total number of study visits and spir-
ometry measurements available for each participant.
Each participant had a minimum of two spirometry
measurements at least 200 days apart, with follow up
ranging from 266 to 1749 days. Exacerbation rate was
measured as the number of patient-reported events re-
quiring health care utilization in the first year after study
enrollment.
Multidetector-row computed tomography (MDCT)
scans at full inspiration and full expiration were per-
formed at the SPIROMICS baseline visit. Emphysema was
defined using a threshold of <− 950 Hounsfield Units on
full inspiration. Airway wall thickening was defined as the
square root of the airway wall area for a standardized air-
way with an internal perimeter of 10 mm (Pi10) [26].
Parametric Response Mapping (PRM) was used to define
functional small airways disease (fSAD), a measure of
non-emphysematous gas trapping, as the percent of voxels
with CT attenuation values > − 950 HU on the inspiratory
exam and < − 856 HU on the expiratory scan, as previ-
ously described [27] using Imbio Lung Density software
(Imbio, Minneapolis, MN).
Statistical analysis
Comparisons of categorical predictors across groups 1, 2
and 3 used chi-squared tests. For continuous variables,
ANOVA was used to test for overall differences between
the 3 groups; pairwise comparisons of continuous out-
comes between any two groups were based on t-tests.
[28] Multivariable linear regression was used to compare
continuous measures (emphysema, fSAD, CT metrics,
6MWD, CAT score, quality of life, FEV1, and FEF25–75)
between groups, adjusted for age, sex, race, smoking his-
tory (pack-years) and current smoking (yes/no). Multi-
variable logistic regression was used to compare binary
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clinical outcomes (emphysema present, fSAD present,
chronic bronchitis, mMRC Dyspnea, and medication use)
adjusted for the same patient characteristics described
above.
Quantile regression models [29] applied to healthy
never -smokers estimated the 95th percentile for PRM
emphysema and, separately, the 95th percentile for PRM
fSAD for a normal patient based on their age, sex, BMI
and the scanner used. Hereafter, these estimated 95th
percentiles will be used to define the upper limit of nor-
mal (ULN) for these PRM measures according to pa-
tient/scanner characteristics. Presence of emphysema or
fSAD was defined when an individual’s observed PRM
emphysema percent or PRM fSAD percent was greater
than the estimated ULN for a normal patient with similar
patient/scanner characteristics. Sensitivity and specificity
of each FEV1/FVC cut-off for identifying individuals with
radiographic CT evidence of smoking-related lung disease
manifest as either emphysema and/or fSAD were
estimated.
Results
We compared the discordant group (Group 1) with
ever-smokers with normal spirometry (Group 2) and
never-smokers (Group 3). The characteristics of the
three groups are shown in Table 1. The discordant group
had more male and white participants and was older
than the other two groups.
Compared with ever-smokers with FEV1/FVC > 0.70
(Group 2), the discordant individuals (Group 1) had
lower post-bronchodilator FEV1% predicted (92.1% vs
97.5%, p < 0.001) and reduced FEF25–75% predicted
(61.2% vs 102.3%, p < 0.001) (Table 2, Fig. 1). The two
groups of ever-smokers did not differ significantly in
6MWD (437.5 vs 437.2 m, p = 0.97), SGRQ (22.5 vs 24.2,
p = 0.28), or CAT score (10.7 vs 11.3, p = 0.36). More
smokers in the discordant group reported regular use of
either inhaled corticosteroids and/or bronchodilators
than either ever-smokers with FEV1/FVC > 0.70, Group
2, (34.4% vs. 25.1%, p = 0.01) or never-smokers, Group 3
(3.9%, p < 0.001). Groups 1 and 2 did not differ in the
reported incidence of chronic bronchitis or moderate or
severe dyspnea indicated by mMRC score ≥ 2. Nor did
they differ with respect to FEV1 decline per year, or ex-
acerbations per year (Table 2).
The discordant group had a modest but significantly
greater percentage of lung with CT scan-defined emphy-
sema than Group 2 (2.1% vs 0.7%, p < 0.001) or Group 3
(0.3%, p < 0.001). Individuals in the discordant group also
had significantly increased PRM fSAD as compared to
Groups 2 and 3 (18.0% vs. 9.1% and 7.1%, respectively, p
< 0.001), without detectable differences in airway thick-
ness (Table 3, Fig. 1). Density plots illustrating the
distribution of emphysema and small airways disease
are presented in supplementary material (Additional file 1:
Figure S1 and Additional file 2: Figure S2).
Using age-adjusted ULN for % emphysema, more individ-
uals in the discordant group met CT criteria for the pres-
ence of emphysema compared with Groups 2 and 3 (38.7%
vs. 17.4% (p < 0.001) and 8.2% (p < 0.001), respectively).
Similarly, using age-adjusted ULN for PRM fSAD, more in-
dividuals in the discordant group also met CT criteria for
the presence of fSAD compared with Groups 2 and 3
(15.3% vs. 7.8% (p= 0.003) and 2.9% (p < 0.001), respect-
ively). In the discordant group, 44% of subjects had CT evi-
dence of smoking-related lung disease, manifest as either
emphysema or fSAD, compared with 20.7% (p < 0.001) of
Group 2 and 9.4% (p < 0.001) of Group 3 subjects. Con-
versely, 56% of individuals in the discordant group had CT
scans without radiographic evidence of smoking-related
lung disease (Table 3, Fig. 2 , Additional file 3: Figure S3).
Within the discordant group, those with CT evidence
of smoking-related lung disease did not have signifi-
cantly greater respiratory symptoms, FEV1 decline, exac-
erbations, or lower FEF25–75 compared with those
without emphysema or fSAD (Table 4).
When compared to a fourth group of smokers with
FEV1/FVC in the 75% quartile of those less than LLN,
Table 1 Baseline characteristics for the three groups
Variable Group 1
Ever-smokers, Normal FEV1,
FEV1
FVC < 0.7 and > LLN
(Discordant Group) (n = 161)
Group 2
Ever-smokers, Normal FEV1,
FEV1
FVC > 0.7
(n = 940)
Group 3
Never-smokers, Normal FEV1,
FEV1
FVC > 0.7
(n = 190)
P-value
Sex (% male) 70.8% 49.0% 37.9% < 0.001*
Race (% white) 89.4% 68.2% 70.7% < 0.001*
Current smoker (%) 32.5% 50.0% 0% < 0.001*
Age (mean ± SD) 69.3 ± 6.4 60.4 ± 9.7 56.6 ± 10.2 < 0.001†
Smoking history in
pack-years (mean ± SD)
48.3 ± 22.2 43.1 ± 27.3 Not Applicable 0.0‡
*Chi-Square test
†ANOVA
‡t-test
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Table 2 Comparison of physiologic and clinical variables between ever-smokers with normal FEV1 and FEV1/FVC > LLN but < 0.70
(“discordant” group), ever-smokers with normal FEV1 and FEV1/FVC > 0.70, and never-smokers with normal FEV1 and FEV1/FVC > 0.70
Clinical Outcome Group 1
Ever-smokers,
Normal FEV1,
FEV1
FVC < 0.7
and > LLN
(Discordant
Group)
(n = 161)
Group 2
Ever-smokers,
Normal FEV1,
FEV1
FVC > 0.7
(n = 940)
Group 3
Never-
smokers,
Normal
FEV1,
FEV1
FVC > 0.7
(n = 190)
Overall p-value*
Unadjusted
(Adjusted)
P-values for pairwise comparisons (Unadjusted)
Group 1 vs. 2 Group 1 vs. 3 Group 2 vs. 3
FEV1% predicted 92.1 ± 12.0 97.5 ± 12.8 102.0 ± 11.5 < 0.001 (< 0.001) < 0.001 < 0.001 < 0.001**
FEF25–75% % predicted 61.2 ± 11.0 102.3 ± 33.4 121.3 ± 32.5 < 0.001 (< 0.001) < 0.001 < 0.001 < 0.001**
6MWD (m) 437.5 ± 109.6 437.2 ± 97.7 479.3 ± 103.4 < 0.001 (0.49) 0.97 < 0.001 < 0.001**
St George’s Respiratory
Questionnaire Total Score
22.5 ± 17.4 24.2 ± 19.1 8.8 ± 10.0 < 0.001 (< 0.001) 0.28 < 0.001 < 0.001**
COPD Assessment Test (CAT) 10.7 ± 7.4 11.3 ± 8.1 4.7 ± 6.0 < 0.001 (< 0.001) 0.36 < 0.001 < 0.001**
Use of either inhaled
corticosteroid or bronchodilator
34.4% 25.1% 3.9% < 0.001 (< 0.001) 0.01 < 0.001 < 0.001†
Chronic bronchitis 17.3% 17.8% 2.1% < 0.001 (< 0.001) 0.88 < 0.001 < 0.001†
mMRC Dyspnea score≥ 2 13.8% 13.6% 2.7% < 0.001 (0.007) 0.95 < 0.001 < 0.001†
Change in FEV1 (ml/year) − 60.5 ± 120.5 −55.2 ± 127.5 −41.2 ± 99.7 0.32
(0.94)
0.64 0.17 0.19**
Exacerbation (#/year) 0.1 ± 0.4 0.1 ± 0.6 0.02 ± 0.1 0.02
(0.21)
0.50 0.13 0.006**
Emphysema =% of voxels with CT attenuation <− 950 Hounsfield Units (HU) on full inspiration. Functional small airways disease = % of voxels with CT attenuation
> − 950 HU on the inspiratory exam and < − 856 HU on the expiratory scan, as determined via dynamic image registration (Parametric Response Mapping, PRM).
Airway thickening = square root of the wall area for a standardized airway with an internal perimeter of 10 mm (Pi10)
*From likelihood ratio test comparing means of 3 groups from multivariable model with outcomes (rows) and group status as predictors adjusted for age, sex,
race, smoking history (pack-years) and current smoking
**p-values from 2 sample t-test
†Pairwise p-value form Wald test comparing means of 2 groups
Fig. 1 Box plots demonstrating percent of predicted forced expiratory volume in 1 s (FEV1%), forced expiratory flow rate between 25 and 75% of
forced vital capacity (FEF25–75%), percent emphysema, and functional small airways disease by parametric response mapping (fSAD) in the three groups
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Table 3 Comparison of CT variables between ever-smokers with normal FEV1 and FEV1/FVC > LLN but < 0.70 (“discordant” group),
ever-smokers with normal FEV1 and FEV1/FVC > 0.70, and never-smokers with normal FEV1 and FEV1/FVC > 0.70
Variable Group 1
Ever-smokers,
Normal FEV1,
FEV1
FVC < 0.7 and > LLN
(Discordant Group)
(n = 161)
Group 2
Ever-
smokers,
Normal
FEV1,
FEV1
FVC > 0.7
(n = 940)
Group 3
Never-
smokers,
Normal
FEV1,
FEV1
FVC > 0.7
(n = 190)
Overall p-value*
from likelihood
ratio test
comparing
association with
group status
Unadjusted
(Adjusted)
P-values for pairwise comparisons (Unadjusted)
Group 1 vs. 2 Group 1 vs. 3 Group 2 vs. 3
Emphysema (%) 2.1 ± 2.9 0.7 ± 2.6 0.3 ± 0.9 < 0.001
(< 0.001)
< 0.001 < 0.001 < 0.001**
Functional small airways disease (%) 18.0 ± 10.6 9.1 ± 10.0 7.1 ± 8.3 < 0.001
(< 0.001)
< 0.001 < 0.001 < 0.001**
Airway wall thickening (Pi10) 3.70 ± 0.01 3.71 ± 0.00 3.69 ± 0.01 < 0.001
(0.17)
0.41 0.01 < 0.001**
Emphysema present > ULN 38.7% 17.4% 8.2% < 0.001
(< 0.001)
< 0.001 < 0.001 0.004†
CT-defined functional small airway
abnormality (fSAD) present > ULN
15.3% 7.8% 2.9% < 0.001
(0.03)
0.003 < 0.001 0.03†
Either emphysema or fSAD present 44% 20.7% 9.4% < 0.001 (< 0.001) < 0.001 < 0.001 < 0.001†
Both emphysema and fSAD present 10% 4.5% 1.8% 0.002 (0.23) 0.007 0.005 0.11†
Presence of emphysema = ≥ upper limit of normal (ULN); Presence of fSAD = ≥ upper limit of normal (ULN). Emphysema =% of voxels with CT
attenuation <− 950 Hounsfield Units (HU) on full inspiration. Functional small airways disease = % of voxels with CT attenuation > − 950 HU on
the inspiratory exam and < − 856 HU on the expiratory scan, as determined via dynamic image registration (Parametric Response Mapping, PRM)
*From likelihood ratio test comparing means of 3 groups from multivariable model with outcomes (rows) and group status as predictors adjusted
for age, sex, race, smoking history (pack-years) and current smoking
**P-value from 2 sample t test
†Pairwise p-value form Wald test comparing means of 2 groups
Fig. 2 Percent of patients in each group with emphysema and functional small airways disease (fSAD) present greater than the age-adjusted
upper limit of normal (ULN) as measured by parametric response mapping (PRM) on chest CT
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the discordant group had higher FEV1 and FEF25–75%,
fewer respiratory symptoms and exacerbations, less air-
way wall thickness and fewer % of people with fSAD,
however did not differ in the amount of emphysema or
FEV1 decline (Additional file 4: Tables S1, S2 and S3).
A history of smoking had a significant association with
symptoms in groups defined by either FEV1/FVC thresh-
old compared to never-smokers. When compared with
never-smokers without airflow obstruction, both groups
of ever-smokers had more chronic bronchitis, dyspnea,
respiratory symptoms as measured by CAT, and lower
quality of life by SGRQ (Table 2).
Finally, we evaluated the sensitivity and specificity of the
two thresholds for FEV1/FVC for identification of individ-
uals with radiographic evidence of smoking-related lung
disease (emphysema > age-adjusted ULN and/or PRM
fSAD > age-adjusted ULN). A threshold of FEV1/FVC
< 0.7 had a sensitivity of 0.85 and specificity of 0.72 for
identifying any radiographic abnormality. The FEV1/FVC
< LLN threshold had lower calculated sensitivity (0.78)
and higher specificity (0.81) (Table 5). Thus the absolute
ratio is more sensitive, while the LLN is more specific.
Discussion
In the SPIROMICS cohort, current or former smokers
with normal FEV1 who are diagnosed with COPD based
on GOLD spirometric criteria, but who do not have
airflow obstruction based on the LLN threshold, have
more emphysema and functional small airways disease by
CT, increased use of inhaled medications, and lower
mid-expiratory flow compared with current or former
smokers without airway obstruction, defined by FEV1/
FVC > 0.70. Almost half of individuals in this discordant
group have CT evidence of smoking-related lung disease.
Nevertheless, the discordant group did not have increased
respiratory symptoms (chronic bronchitis, dyspnea, or
CAT) or decreased exercise tolerance when compared
with individuals with FEV1/FVC ratio > 0.7.
We have focused this analysis on individuals in this dis-
cordant group for three reasons. First, in reference popu-
lations the ratio of FEV1/FVC decreases with advancing
age, suggesting that use of a fixed threshold of 0.7 may in-
appropriately classify some individuals. Second, studies of
this population may help elucidate the boundaries of nor-
mal aging in the setting of cigarette smoking. Finally, there
has been recent interest in the clinical picture of smokers
who may have smoking-related lung disease in the setting
of little or no airflow obstruction [17, 18]. This study con-
tributes to the discussion in each of these three areas.
Our findings support the presence of early/mild dis-
ease among individuals in this discordant group and
thus provide potential pathophysiologic explanation for
previous studies demonstrating increased risk for
COPD-related health effects in this group, including in-
creased adjusted risk of death, COPD-related emergency
department visits and hospitalizations [13, 15]. These
studies suggest that the LLN threshold lacks sensitivity,
failing to identify a number of individuals with clinically
significant disease.
However, because the predicted FEV1/FVC may de-
cline with normal age, using a fixed cut-off ratio of
FEV1/FVC < 0.70 increases diagnosis of obstruction in
the elderly, and in very old adults has the potential to
classify changes associated with aging as COPD [4–9].
In a cohort of adults 80 years and older, airflow obstruc-
tion defined by FEV1/FVC < LLN, but not FEV1/FVC be-
tween LLN and 0.70, was associated with increased
mortality [4]. Similarly, small amounts of emphysema
may occur due to aging-related changes rather than as a
consequence of early smoking-related disease. In the
multiethnic MESA cohort, full-lung CT scans of healthy
Table 4 Comparison of prospective FEV1 decline, exacerbation rate and respiratory symptoms between those in the discordant
group (Ever-smokers with normal FEV1, FEV1/FVC < 0.70 and > LLN) with CT findings of emphysema or functional small airways
disease, and those without
Ever-smokers with normal FEV1, FEV1/FVC < 0.70 and > LLN (discordant group, n = 161)
With fSAD or
emphysema (44%)
Without fSAD or emphysema (56%) *Adjusted
p-value
Unadjusted
p-value
Annual change in FEV1 (ml/year) −65.6 ± 113.0 −59.8 ± 130.6 0.26 0.79
Exacerbation (#/year) 0.13 ± 0.42 0.06 ± 0.24 0.90 0.25
COPD Assessment Test (CAT) 11.43 ± 7.44 9.88 ± 7.25 0.55 0.22
Chronic bronchitis (%) 14.3 ± 35.3 18.3 ± 38.9 0.58 0.52
FEF25–75% % predicted 60.0 ± 11.6 62.2 ± 10.7 0.87 0.24
*Multivariate model adjusting for age, gender, race, pack year, and current smoking status
Table 5 Calculated sensitivity and specificity for diagnosis of
COPD defined by presence of radiographic CT evidence of
smoking related lung disease, with emphysema > age adjusted
upper limit of normal and/or functional small airways disease >
ULN. N = 2972. LLN = lower limit of normal
Diagnostic criteria Sensitivity Specificity
FEV1/FVC < 0.7 0.85 0.72
FEV1/FVC < LLN 0.78 0.81
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nonsmokers revealed a small percent of emphysema
(median 1.1%) that was increased in men and with age.
[30] CT-defined functional small airway abnormality also
increases with age [31]. Therefore, the predicted “nor-
mal” amount of emphysema and small airways disease
increases with aging even in the absence of smoking
exposure. An important question is how to distinguish
between early/mild COPD and normal aging. In our
study we used data from normal individuals to create
age-adjusted upper limits of normal for both emphysema
and PRM fSAD, suggesting that the CT abnormality we
have identified in the discordant group is beyond that
associated with normal aging. Our study extends previ-
ous findings by including innovative imaging parameters
of small airways disease and comparisons with normal
lung density [16].
We found significantly reduced FEF25–75% and CT scan
evidence of non-emphysematous air trapping in the dis-
cordant group. Reduction in mid-expiratory flow is gener-
ally assumed to be an indication of small airways disease
[32–34]. We did not identify differences in airway wall
thickness, manifest as path specific Pi10, associated with
our discordant group. However, changes in lumen dimen-
sion may mask changes in wall thickening/thinning by this
parameter [35]. CT air trapping is also thought to reflect
small airways disease and has been associated with lower
lung function and accelerated lung function decline [36,
37]. The functional small airways disease measurement
using PRM helps to distinguish non-emphysematous air
trapping from emphysema on CT [27]. Thus physiologic
and CT scan data both point to subtle but potentially clinic-
ally important small airways abnormalities in this discord-
ant group. Several studies have suggested that in the
natural history of COPD, small airways may become nar-
rowed or lost prior to the onset of emphysema [34, 38–40]
and thus these abnormalities may be an earlier indication
of smoking-related COPD. We evaluated two prospective
variables: exacerbations in the first year after enrollment,
and FEV1 decline over a period of up to 4 years. Though
we did not detect more FEV1 decline or exacerbations in
the discordant group or those with radiographic emphy-
sema or fSAD, exacerbation rate was overall low in these
patients with mild smoking-related lung disease. Longer
follow up time will enhance our understanding of the sig-
nificance of these mild radiographic and physiologic abnor-
malities as predictors of progression to COPD.
The choice of a threshold of FEV1/FVC for diagnosing
airflow obstruction may depend on the goals of testing
and whether a more sensitive or specific test is preferred.
In the SPIROMICS cohort, using a FEV1/FVC threshold
of 0.70 is more sensitive but less specific for identifying in-
dividuals with radiographic manifestations of COPD, while
using LLN is more specific but less sensitive. As a screening
test for early/mild disease in ever-smokers, a more sensitive
test may be preferred. However, identifying airflow obstruc-
tion using either FEV1/FVC threshold will incorrectly clas-
sify individuals.
There are several important features of this study.
SPIROMICS is a large multi-center cohort whose sub-
jects are extensively characterized for symptoms, physi-
ology and radiology. MDCT scans performed at baseline
allowed detailed assessment of emphysema, air trapping,
and airway wall thickness and image analysis by PRM
allowed differentiation of non-emphysematous air trap-
ping from emphysema on CT. We recognize several lim-
itations to our study. FEF25–75% is an effort-dependent
measurement like FEV1 and we cannot exclude a con-
founding effect of limited effort or frailty. However, the
subjects described in this report all had studies that met
ATS criteria and had normal FVC. The specificity statis-
tic is biased because the analysis data set is not a ran-
dom sample. Additionally, never-smokers with FEV1/
FVC < 0.7 were not included in SPIROMICS and thus
could not be compared in this analysis.
Conclusions
Ever-smokers who have normal FEV1 and FEV1/FVC
< 0.70 but > LLN (discordant group) have on average
more emphysema and small airways disease, and in-
creased respiratory medication use compared with those
with FEV1/FVC > 0.70. This is a heterogeneous group that
includes a large number of individuals with CT evidence
of either emphysema or non-emphysematous gas trap-
ping, as well as many individuals without radiographic evi-
dence of early smoking-related lung disease for whom it is
likely that normal aging accounts for the apparent spiro-
metric abnormality. The diagnosis of early/mild COPD re-
quires a more sophisticated approach that goes beyond
currently accepted spirometric criteria.
Endnotes
1Some of the results of these studies have been previ-
ously reported in the form of an abstract [41, 42].
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